Novo Nordisk announced new phase 3 CagriSema findings on September 21, 2026. The news concerns two different trial settings. Keeping them separate is essential before drawing conclusions about the investigational combination.
What the company announced
In REIMAGINE 5, Novo reported average weight reductions of 12.4% with CagriSema 1.0 mg/1.0 mg and 9.1% with tirzepatide 5 mg at 60 weeks in adults with type 2 diabetes. The figures use the efficacy estimand. The company also reported non-inferiority for the blood-sugar endpoint, HbA1c.
REDEFINE 9 compared CagriSema with placebo in people with overweight or obesity. That is a separate comparison; it does not extend the tirzepatide finding to every obesity population.
Sources: Novo Nordisk — company announcement
Why the comparator matters
Our interpretation: a headline about superiority should travel with the dose and population that produced it. A comparison against one tirzepatide dose cannot answer how every approved dose would perform. Likewise, results in a diabetes population should not be casually substituted for results in a population without diabetes.
A useful reading habit is to write the comparison as a full sentence: which treatment, against what alternative, for whom, and over how long? If a headline drops one of those elements, open the source before sharing it.
What remains to be assessed
This is a company topline announcement. Readers should look for detailed participant flow, discontinuations, adverse-event tables, confidence intervals, and the analysis that accounts for stopping treatment. Those details can change how a large average result translates into expectations for an individual.
CagriSema combines cagrilintide with semaglutide. Novo still described it as investigational in this release. A positive study announcement is a different milestone from regulatory approval.
Sources: Novo Nordisk — company announcement · U.S. FDA
Conclusion
The useful headline is a specific clinical comparison, not a universal ranking. Keep the trial population and comparator attached to the numbers, and look for the full report as it becomes available.